Kyverna Therapeutics Common Stock Beta
| KYTX Stock | 8.70 0.76 9.57% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Kyverna Therapeutics' long-term financial health and intrinsic value.
Kyverna | Beta | Build AI portfolio with Kyverna Stock |
Kyverna Therapeutics Common Company Beta Analysis
Kyverna Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Kyverna Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Kyverna Therapeutics is extremely important. It helps to project a fair market value of Kyverna Stock properly, considering its historical fundamentals such as Beta. Since Kyverna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kyverna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kyverna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Kyverna Therapeutics Common has a Beta of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The beta for all United States stocks is 100.0% lower than that of the firm.
Kyverna Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kyverna Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kyverna Therapeutics could also be used in its relative valuation, which is a method of valuing Kyverna Therapeutics by comparing valuation metrics of similar companies.Kyverna Therapeutics is currently under evaluation in beta category among its peers.
Kyverna Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kyverna Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kyverna Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Kyverna Fundamentals
| Return On Equity | -0.71 | ||||
| Return On Asset | -0.41 | ||||
| Current Valuation | 356.64 M | ||||
| Shares Outstanding | 59.61 M | ||||
| Shares Owned By Insiders | 9.10 % | ||||
| Shares Owned By Institutions | 53.22 % | ||||
| Number Of Shares Shorted | 3.49 M | ||||
| Price To Book | 3.44 X | ||||
| Gross Profit | (137.19 M) | ||||
| EBITDA | (125.2 M) | ||||
| Net Income | (127.48 M) | ||||
| Total Debt | 8.24 M | ||||
| Book Value Per Share | 3.47 X | ||||
| Cash Flow From Operations | (114.25 M) | ||||
| Short Ratio | 2.37 X | ||||
| Earnings Per Share | (3.73) X | ||||
| Target Price | 29.6 | ||||
| Number Of Employees | 129 | ||||
| Market Capitalization | 484.6 M | ||||
| Total Asset | 304.64 M | ||||
| Retained Earnings | (263.52 M) | ||||
| Working Capital | 256.85 M | ||||
| Net Asset | 304.64 M |
About Kyverna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kyverna Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kyverna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kyverna Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Additional Tools for Kyverna Stock Analysis
When running Kyverna Therapeutics' price analysis, check to measure Kyverna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kyverna Therapeutics is operating at the current time. Most of Kyverna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kyverna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kyverna Therapeutics' price. Additionally, you may evaluate how the addition of Kyverna Therapeutics to your portfolios can decrease your overall portfolio volatility.